

CITATION REPORT

List of articles citing

Evaluation of absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor

DOI: 10.1080/00498254.2020.1737759
Xenobiotica, 2020, 50, 1032-1042.

Source: <https://exaly.com/paper-pdf/77045708/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
19	Drug-Drug Interactions at Organic Cation Transporter 1. <i>Frontiers in Pharmacology</i> , 2021 , 12, 628705	5.6	5
18	Prostate cancer and PARP inhibitors: progress and challenges. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 51	22.4	14
17	Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 88, 259-270	3.5	2
16	A high-throughput cell-based gaussia luciferase reporter assay for measurement of CYP1A1, CYP2B6, and CYP3A4 induction. <i>Xenobiotica</i> , 2021 , 51, 752-763	2	2
15	Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advanced testing. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 635-653	5.5	7
14	Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	6
13	A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 88, 887-897	3.5	0
12	PARPs in lipid metabolism and related diseases. <i>Progress in Lipid Research</i> , 2021 , 84, 101117	14.3	9
11	Metabolism-related pharmacokinetic drug-drug interactions with poly (ADP-ribose) polymerase inhibitors (Review). <i>Oncology Reports</i> , 2022 , 47,	3.5	0
10	Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 851246	5.6	0
9	PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	0
8	Clinical Aspects of Drug-Drug Interaction and Drug Nephrotoxicity at Renal Organic Cation Transporters 2 (OCT2) and Multidrug and Toxin Exclusion 1, and 2-K (MATE1/MATE2-K).. <i>Biological and Pharmaceutical Bulletin</i> , 2022 , 45, 382-393	2.3	0
7	Appropriate Selection of PARP Inhibitors in Ovarian Cancer.. <i>Current Treatment Options in Oncology</i> , 2022 , 23, 887	5.4	2
6	Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. 2022 ,		0
5	Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.		0
4	Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.		1
3	Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations. Volume 14, 3159-3174		0

- 2 Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects. ○
- 1 Combined oral contraceptives as victims of drug interactions. DMD-MR-2022-000854 ○